Présentation de l'entreprise
Daxor Corporation operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry by developing and commercializing medical instrumentation and biotechnology solutions. The company's core product offering is the BVA-100 Blood Volume Analyzer, an instrument designed to measure human blood volume, which functions in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. As a publicly traded entity with the ticker symbol DXR, the company currently holds a market capitalization of $52.88 million, indicating its position as a small-cap stock within the financial landscape. With an annual revenue of $26,688 and an employee count listed as unavailable, the company's scale suggests a specialized operational model rather than broad-scale manufacturing, which often characterizes firms with significantly larger market capitalizations and revenue streams.
Santé financière
The company reported a revenue of $26,688 over the trailing twelve months, while generating a net income of $9.17 million and an EBITDA figure that is not available in the provided data. The substantial disparity between the reported revenue of $26,688 and the net income of $9.17 million reveals a highly anomalous cost structure where expenses appear to be negative or non-existent in the standard accounting sense, resulting in a net income that mathematically exceeds total revenue. Free cash flow stands at $100,248, which suggests a theoretical capacity for financial flexibility, though this figure must be interpreted alongside the unique margin anomalies present in the dataset. The gross margin is reported at 100.0%, indicating that the cost of goods sold is effectively zero relative to sales, whereas the operating margin is -9660.6%, pointing to significant non-operating expenses or accounting adjustments that distort traditional operating performance metrics. In contrast, the profit margin is listed as 34359.2%, further highlighting the extreme volatility or specific accounting treatment affecting the bottom line relative to revenue. Regarding liquidity and solvency, the company reports zero debt and an unavailable cash balance, while the debt-to-equity ratio is not available, yet the presence of zero debt suggests a technically conservative leverage position despite the liquidity concerns raised by other metrics. The current ratio is recorded at 0.08, which indicates a severe short-term liquidity constraint where current liabilities significantly exceed current assets, potentially raising questions about the company's ability to meet immediate obligations. Return on equity is calculated at 22.5%, suggesting high efficiency in generating shareholder value from equity, while return on assets is -1.6%, revealing that the company's asset base is currently generating a negative return on an asset level basis.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is 5.53, whereas the forward P/E ratio is not available, creating an asymmetry that prevents a clear comparison of current valuation against expected future earnings growth trajectories. The price-to-book ratio is exactly 1.00, which indicates that the market is currently pricing the company's shares at a level equal to its book value, suggesting no immediate market premium or discount relative to the net asset value. The price-to-sales ratio is exceptionally high at 1981.49, and since the EV/EBITDA ratio is not available, these alternative metrics suggest a valuation model heavily reliant on earnings per share rather than sales or enterprise value multiples. The stock has traded within a 52-week range defined by a high of $14.76 and a low of $7.10, meaning the current market price sits somewhere within this historical band, reflecting the volatility typical of small-cap healthcare firms. The beta coefficient is 0.14, which implies that the stock price is significantly less volatile than the broader market, moving with much lower sensitivity to general market fluctuations compared to large-cap indices.
Growth & Income
Revenue growth year-over-year is -82.6%, while earnings growth year-over-year is 329.3%, indicating that earnings are growing at a pace vastly disproportionate to the decline in revenue, likely driven by the unique margin structure discussed in the financial health section. The company does not pay dividends, evidenced by a dividend yield of not available and a payout ratio of 0.0%, meaning that all generated earnings are retained within the company rather than distributed to shareholders. This retention strategy implies that the company prioritizes reinvesting earnings into growth initiatives, such as research and development for its blood volume analyzer technology, rather than providing immediate income to investors. Overall, the growth and income profile is characterized by a complete absence of dividend income combined with extreme earnings volatility that decouples from revenue trends, presenting a high-risk, high-reward financial scenario for holders of DXR shares.